Market Exclusive

SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Submission of Matters to a Vote of Security Holders

SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.

On July30, 2018, SteadyMed Ltd. (the “Company”) held an extraordinary general meeting of its shareholders (the “Meeting”). The required quorum was present. The following is a summary of the proposals and the voting results from the Meeting. A complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June25, 2018, as supplemented by the definitive additional materials filed with the Securities and Exchange Commission on June29, 2018 and July16, 2018 (together, the “Proxy Statement”).

Proposal 1 — Approval of the Agreement and Plan of Merger and the Merger. The Company’s shareholders approved the Agreement and Plan of Merger, dated as of April29, 2018, by and among the Company, United Therapeutics Corporation, and Daniel 24043 Acquisition Corp. Ltd. (the “Merger Agreement”), the terms of the merger contemplated thereby, and all other documents, agreements and transactions contemplated under or related thereto, including the Contingent Value Rights Agreement attached thereto and the warrant amendments between Messrs.Brian J. Stark, Keith Bank, Ron Ginor, each a director of the Company, and/or their affiliates, and the Company. The voting results are as follows:

For

Against

Abstain

20,917,435

62,240

1,286

As required by the Israeli Companies Law, this proposal received a majority of the votes of the shareholders, excluding abstentions, present at the Meeting in person or by proxy (i) who are not United Therapeutics Corporation or Daniel 24043 Acquisition Corp. Ltd. (or any other person who holds 25% or more of the means of control of Daniel 24043 Acquisition Corp.) or anyone acting on their behalf (including relatives or corporations controlled by such persons) and (ii)who do not have a “Personal Interest” (as described in the Proxy Statement) in Proposal 1.

Proposal 2 — Golden Parachute Payments. The Company’s shareholders approved, on a non-binding, advisory basis, certain compensation that will be paid or may become payable to the Company’s named executive officers in connection with the transactions contemplated by the Merger Agreement and ancillary agreements. The voting results are as follows:

For

Against

Abstain

17,905,155

2,585,741

490,065

About SteadyMed Ltd. (NASDAQ:STDY)
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company’s ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting.

Exit mobile version